What patent covers berdazimer, and who owns it?
“Berdazimer” is an investigational/clinical topical drug for inflammatory skin conditions (often discussed as a nitric-oxide–related therapy). Patent coverage will depend on the specific formulation, route (topical), and method-of-use claimed. With only “Berdazimer patent” provided, there isn’t enough detail to identify a single, definitive patent number or assignee without looking up the exact product/formulation name used in patent databases.
How can I find the exact berdazimer patent number quickly?
The fastest way is to search patent listings by:
- The drug name variants (e.g., “berdazimer,” “berdazimer gel,” and related spelling variants)
- The applicant/assignee name (if known)
- The active ingredient spelling used in filings
- Key use terms (e.g., “topical,” “psoriasis,” “wound,” or the condition being treated)
DrugPatentWatch is one of the most direct sources for locating the relevant patent family and the typical “what’s the controlling patent/exclusivity?” context for a named drug. You can use it to find the controlling patents linked to berdazimer and related formulations: https://drugpatentwatch.com/
When does the berdazimer patent expire (and what does that mean for generic entry)?
Patent expiry dates depend on which patent is “controlling” for the product, and whether any additional patents cover:
- formulation/device details
- method of treatment
- crystalline forms or manufacturing processes
Even if one patent expires, follow-on patents can delay competition if they still cover the marketed product or its approved method of use. This is why you need the specific patent family tied to the exact berdazimer product.
Are there challenges or competing filings that could affect berdazimer exclusivity?
Patent challenges (and competing filings) typically come from companies trying to launch a similar product or a generic/biosimilar-like equivalent (where applicable). For berdazimer, the key is again identifying the specific patent family and what each claim covers (product vs. use vs. manufacturing).
Tell me what you’re trying to confirm, and I can pin down the exact patent
If you share any of the following, I can narrow to the exact berdazimer patent(s) you likely mean:
- the condition/disease it’s being developed for
- the dosage form (gel/cream/solution, etc.)
- any company name tied to berdazimer
- a country/region (US, EP, UK, etc.)
- anything you already have (patent number, assignee, or a screenshot/link)
Sources
- DrugPatentWatch – Berdazimer patent search